RxDoctor Payments Data

Emily Garner

Nurse Practitioner · Saint Louis, MONPI 1588149553

Payments from drug & device makers

$5,625in general payments, 2019–2025

Across 102 payments — averaging $55.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Biosense Webster, Inc.$1K
  • Boston Scientific$992
  • Kestra Medical Technology Services, Inc.$333
  • Abbott$307
  • Lemaitre Vascular, Inc.$193
  • plus $388 from 7 others

What the payments were for

  • Travel & lodging$1,44326%
  • Food & beverage$4,13774%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,625 in reported general payments places this provider in the 90th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$15,734
Medicare patients
199
Services billed
242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban368$285,265
XareltoRivaroxaban136$110,708
EntrestoSacubitril/Valsartan48$33,205
FarxigaDapagliflozin Propanediol18$10,658
Dofetilide53$7,033
Flecainide Acetate127$4,838
Metoprolol Succinate255$1,819
Diltiazem 24hr Er (Cd)Diltiazem Hcl70$1,727
SotalolSotalol Hcl53$1,323
Eplerenone22$1,187
Potassium Chloride26$464
Amiodarone Hcl28$394
Dilt-XrDiltiazem Hcl18$364
Metoprolol Tartrate36$307
Amlodipine Besylate80$227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$16$110,708136 claims
AstraZenecaFarxiga$71$10,65818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →